The startup develops pathway-selective drugs that target G-protein coupled receptors to minimize adverse effects and enhance therapeutic efficacy. Their validated drug discovery technology offers a lower-risk alternative to traditional methods, enabling effective treatment of diseases related to neuroscience, pain, metabolic disorders, gastroparesis, and inflammation.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods targeting G-protein coupled receptors (GPCRs) often result in off-target adverse effects, limiting the therapeutic index and hindering effective treatment of various diseases. These non-selective interactions can lead to safety concerns and reduced efficacy, particularly in sensitive areas like neuroscience and pain management.
Solution
Mebias Discovery utilizes a proprietary membrane protein-NMR drug discovery platform to identify molecules that selectively bind to GPCR targets, minimizing off-target interactions and enhancing therapeutic efficacy. This approach allows for the development of pathway-selective drugs with a reduced risk of adverse effects. By focusing on protein conformation, the platform identifies molecules that precisely modulate GPCR signaling, leading to more targeted and effective treatments. The company's lead Investigational New Drug (IND), MEB-1170, is currently in Phase 1 clinical trials for opioid use disorder and has demonstrated no abuse potential in preclinical studies. Additionally, Mebias is developing Sphingosine 1-phosphate receptor agonists for neuropathic pain and neuroinflammation.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel drug candidates with improved safety profiles, as well as clinicians and patients in need of more effective and targeted treatments for opioid use disorder, neuropathic pain, and neuroinflammation.
Features
- Proprietary membrane protein-NMR drug discovery platform for identifying selective GPCR-binding molecules
- Pathway-selective drug design to minimize off-target adverse effects
- MEB-1170: A mu-opioid receptor targeting drug in Phase 1 clinical trials for opioid use disorder
- Development of Sphingosine 1-phosphate receptor agonists for neuropathic pain and neuroinflammation
- Preclinical studies demonstrating no abuse potential for MEB-1170